Last reviewed · How we verify

Regorafenib (BAY73-4506) — Competitive Intelligence Brief

Regorafenib (BAY73-4506) (Regorafenib (BAY73-4506)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multikinase inhibitor. Area: Oncology.

phase 3 Multikinase inhibitor VEGFR1-3, FGFR, TIE2, KIT, RET, RAF-1, BRAF Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Regorafenib (BAY73-4506) (Regorafenib (BAY73-4506)) — Bayer. Regorafenib is a multikinase inhibitor that blocks multiple receptor tyrosine kinases involved in tumor angiogenesis, stromal signaling, and oncogenic signaling.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Regorafenib (BAY73-4506) TARGET Regorafenib (BAY73-4506) Bayer phase 3 Multikinase inhibitor VEGFR1-3, FGFR, TIE2, KIT, RET, RAF-1, BRAF
Trifluridine/Tipiracil + Regorafenib Trifluridine/Tipiracil + Regorafenib Second Affiliated Hospital, School of Medicine, Zhejiang University phase 3 Nucleoside analog + multikinase inhibitor combination Thymidylate synthase (trifluridine/tipiracil); VEGFR, FGFR, KIT, RET, BRAF (regorafenib)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multikinase inhibitor class)

  1. Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Regorafenib (BAY73-4506) — Competitive Intelligence Brief. https://druglandscape.com/ci/regorafenib-bay73-4506. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: